The bark giving diabetes therapy some bite: the SGLT inhibitors
- 22 August 2018
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 61 (10), 2075-2078
- https://doi.org/10.1007/s00125-018-4673-4
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairmentDiabetologia, 2016
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Diabetologia, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetesDiabetologia, 2015
- Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?Diabetologia, 2015
- Medications for type 2 diabetes: how will we be treating patients in 50 years?Diabetologia, 2015
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia, 2015
- The relation of glycosuria to glycaemia and the determination of the renal threshold for glucoseBiochemical Journal, 1931
- On the mechanism of sugar elimination in phlorrhizin glycosuria. A contribution to the filtration-reabsorption theory on kidney functionJournal Of Physiology-London, 1930
- A Study of Orthoglycaemic Glycosuria with Particular Reference to its Hereditability.Acta Medica Scandinavica, 1927